New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDS5 vs Livagen

DS5 vs Livagen

Side-by-side comparison of key properties, dosing, and research.

Sleep Optimization
DS5
Anti-Aging & Longevity
Livagen
Summary
DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
Estimated 30-60 minutes (peptide degradation)
Short (minutes); gene-regulatory effects are sustained
Admin Route
Subcutaneous, Intranasal (research)
SubQ, Oral
Research
Typical Dose
200-500 mcg per dose
10 mg per day
Frequency
Once nightly
Daily for 10–30 days
Key Benefits
  • Promotes delta-wave (deep) sleep and improves sleep quality
  • May reduce sleep onset latency
  • HPA axis modulation for stress reduction
  • Non-addictive sleep support without tolerance development
  • Potential circadian rhythm normalization
  • Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Generally well-tolerated in research subjects
  • Possible morning grogginess at higher doses
  • Mild blood pressure fluctuations reported with DSIP
  • Limited human safety data for DS5 specifically
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With